Eduard Vrdoljak

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study

Robert E. Coleman, Linda M. Banks, Samia I. Girgis et al. · The Lancet Oncology · 2007 · 427 citations

Medicine, Endocrinology, Oncology +16

Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Joseph A. Sparano, Eduard Vrdoljak, O. Rixe et al. · Journal of Clinical Oncology · 2010 · 219 citations · Full text

Medicine, Oncology, Pharmacology +10

COVID-19 Pandemic Effects on Breast Cancer Diagnosis in Croatia: A Population- and Registry-Based Study

Eduard Vrdoljak, Melita Perić Balja, Zlatko Marušić et al. · The Oncologist · 2021 · 170 citations · Full text

Medicine, Health Sciences, Oncology +17

Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

Tanja Čufer, Eduard Vrdoljak, Rabab Gaafar et al. · Anti-Cancer Drugs · 2006 · 151 citations

Medicine, Oncology, Pharmacotherapy +16

A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer

Tae Won Kim, Anneli Elme, Zvonko Kusić et al. · British Journal of Cancer · 2016 · 72 citations · Full text

Medicine, Cancer Biology, Gastrointestinal Oncology +14